MX2018006495A - Derivados novedosos de diamino piridina. - Google Patents

Derivados novedosos de diamino piridina.

Info

Publication number
MX2018006495A
MX2018006495A MX2018006495A MX2018006495A MX2018006495A MX 2018006495 A MX2018006495 A MX 2018006495A MX 2018006495 A MX2018006495 A MX 2018006495A MX 2018006495 A MX2018006495 A MX 2018006495A MX 2018006495 A MX2018006495 A MX 2018006495A
Authority
MX
Mexico
Prior art keywords
pyridine derivatives
diamino pyridine
compounds
present
jak
Prior art date
Application number
MX2018006495A
Other languages
English (en)
Inventor
Thoma Gebhard
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2018006495A publication Critical patent/MX2018006495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención describe derivados novedosos de diamino piridina que uestran propiedades de modulación de JAK. La presente invención también se refiere a composiciones farmacéuticas que comprenden estos nuevos compuestos, métodos de uso de dichos compuestos en el tratamiento de diversas enfermedades y trastornos que son susceptibles a la modulación de JAK, y procedimientos para preparar los compuestos descritos más adelante.
MX2018006495A 2015-11-26 2016-11-24 Derivados novedosos de diamino piridina. MX2018006495A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15196542 2015-11-26
PCT/IB2016/057105 WO2017089985A1 (en) 2015-11-26 2016-11-24 Diamino pyridine derivatives

Publications (1)

Publication Number Publication Date
MX2018006495A true MX2018006495A (es) 2018-08-15

Family

ID=54705130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006495A MX2018006495A (es) 2015-11-26 2016-11-24 Derivados novedosos de diamino piridina.

Country Status (35)

Country Link
US (3) US10570096B2 (es)
EP (2) EP3380465B1 (es)
JP (1) JP6634157B2 (es)
KR (1) KR102097878B1 (es)
CN (2) CN108349937B (es)
AU (1) AU2016359438B2 (es)
BR (1) BR112018009540A2 (es)
CA (1) CA3005159A1 (es)
CL (1) CL2018001370A1 (es)
CO (1) CO2018005354A2 (es)
CR (1) CR20180285A (es)
CU (1) CU24506B1 (es)
CY (1) CY1123543T1 (es)
DK (1) DK3380465T3 (es)
DO (1) DOP2018000127A (es)
EA (1) EA035899B1 (es)
EC (1) ECSP18041731A (es)
ES (2) ES2916582T3 (es)
HK (1) HK1253530A1 (es)
HR (1) HRP20201662T1 (es)
HU (1) HUE052345T2 (es)
IL (1) IL259360B (es)
LT (1) LT3380465T (es)
MX (1) MX2018006495A (es)
MY (1) MY195905A (es)
PE (1) PE20181071A1 (es)
PH (1) PH12018501019A1 (es)
PL (2) PL3757097T3 (es)
PT (2) PT3380465T (es)
RS (1) RS60946B1 (es)
RU (2) RU2730007C2 (es)
SA (1) SA518391657B1 (es)
SG (1) SG11201803760VA (es)
SI (1) SI3380465T1 (es)
WO (1) WO2017089985A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016359438B2 (en) * 2015-11-26 2019-05-02 Novartis Ag Diamino pyridine derivatives
EP3908279A1 (en) 2019-01-11 2021-11-17 Novartis AG Lta4h inhibitors for the treatment of hidradenitis suppurativa
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
CA2681015C (en) 2007-03-16 2016-06-21 The Scripps Research Institute Inhibitors of focal adhesion kinase
EP2361902A4 (en) 2008-11-21 2012-04-25 Astellas Pharma Inc 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG
MX2011005621A (es) 2008-11-28 2011-06-20 Kowa Co Derivado de piridin-3-carboxiamida.
ES2555491T3 (es) * 2009-01-23 2016-01-04 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
EP2975027A1 (en) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
KR20150068484A (ko) 2012-10-19 2015-06-19 에프. 호프만-라 로슈 아게 Syk 억제제
PE20150953A1 (es) * 2012-11-08 2015-06-20 Bristol Myers Squibb Co Compuestos de piridilo sustituidos con heteroarilo utiles como moduladores de cinasa
KR102195194B1 (ko) 2012-11-08 2020-12-24 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 아미드-치환된 헤테로시클릭 화합물
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
JP2015014960A (ja) 2013-07-05 2015-01-22 ソニー株式会社 情報処理装置、および記憶媒体
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
EP3226848A4 (en) 2014-12-03 2019-04-03 Phio Pharmaceuticals Corp. METHODS OF TREATING ALOPECIA IN AREA USING GENETIC MODULATION APPROACHES
AU2016359438B2 (en) * 2015-11-26 2019-05-02 Novartis Ag Diamino pyridine derivatives

Also Published As

Publication number Publication date
RU2018122953A3 (es) 2020-01-29
MY195905A (en) 2023-02-27
SG11201803760VA (en) 2018-06-28
CL2018001370A1 (es) 2018-07-27
CY1123543T1 (el) 2022-03-24
US10570096B2 (en) 2020-02-25
IL259360B (en) 2021-05-31
RU2730007C2 (ru) 2020-08-14
CU20180044A7 (es) 2018-10-04
CO2018005354A2 (es) 2018-05-31
PL3757097T3 (pl) 2022-07-25
DOP2018000127A (es) 2018-10-31
JP6634157B2 (ja) 2020-01-22
EA035899B1 (ru) 2020-08-28
WO2017089985A1 (en) 2017-06-01
PT3380465T (pt) 2020-10-23
IL259360A (en) 2018-07-31
RU2018122953A (ru) 2019-12-26
SA518391657B1 (ar) 2021-02-22
BR112018009540A2 (pt) 2018-11-06
HUE052345T2 (hu) 2021-04-28
CA3005159A1 (en) 2017-06-01
US20180354904A1 (en) 2018-12-13
KR20180067681A (ko) 2018-06-20
US20200140386A1 (en) 2020-05-07
PH12018501019A1 (en) 2018-12-17
EP3757097B1 (en) 2022-03-30
ES2916582T3 (es) 2022-07-01
EP3380465B1 (en) 2020-08-05
RS60946B1 (sr) 2020-11-30
US11274080B2 (en) 2022-03-15
AU2016359438A1 (en) 2018-05-31
CN108349937A (zh) 2018-07-31
EA201891258A1 (ru) 2018-10-31
ECSP18041731A (es) 2018-06-30
DK3380465T3 (da) 2020-10-26
PL3380465T3 (pl) 2021-01-25
CU24506B1 (es) 2021-04-07
JP2019503343A (ja) 2019-02-07
HK1253530A1 (zh) 2019-06-21
ES2829052T3 (es) 2021-05-28
CN108349937B (zh) 2021-02-09
SI3380465T1 (sl) 2020-11-30
AU2016359438B2 (en) 2019-05-02
EP3757097A1 (en) 2020-12-30
HRP20201662T1 (hr) 2020-12-25
CN112851578A (zh) 2021-05-28
CR20180285A (es) 2018-07-16
PE20181071A1 (es) 2018-07-04
PT3757097T (pt) 2022-06-20
RU2020124922A (ru) 2020-08-10
LT3380465T (lt) 2020-11-10
KR102097878B1 (ko) 2020-04-06
US20220177432A1 (en) 2022-06-09
EP3380465A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
MX2021000848A (es) Compuestos y sus usos para modular la hemoglobina.
MX2015011769A (es) Compuestos y sus usos para modular la hemoglobina.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
NZ757081A (en) Somatostatin modulators and uses thereof
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2018003563A (es) Nuevos compuestos.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
CY1123543T1 (el) Παραγωγα διαμινοπυριδινης
PH12019500198A1 (en) Compounds and compositions and uses thereof
TW201713686A (en) Methods for preparing modified von Willebrand factor
PH12016501613B1 (en) Pyrazines modulators of gpr6
MX2017009608A (es) Compuestos anticancerigenos.
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.